Kaleido Biosciences's latest marketcap:
As of 08/02/2025, Kaleido Biosciences's market capitalization has reached $4,262. According to our data, Kaleido Biosciences is the 49729th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 4,262 |
| Revenue (ttm) | 1.1 M |
| Net Income (ttm) | -90,288,000 |
| Shares Out | 42.62 M |
| EPS (ttm) | -2.16 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
Kaleido Biosciences's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/02/2025 | $4,262 | 9811.63% | 49729 |
| 12/31/2024 | $43 | 0% | 48380 |
| 12/29/2023 | $43 | -99.8% | 46705 |
| 12/30/2022 | $21,311 | -99.98% | 44963 |
| 12/31/2021 | $101.8 M | -68.91% | 42929 |
| 12/31/2020 | $327.44 M | 117.13% | 39697 |
| 12/31/2019 | $150.8 M | 36987 |
Company Profile
About Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on developing innovative microbiome metabolic therapies. Founded in 2015 and headquartered in Lexington, Massachusetts, the company pioneers novel treatments for a range of medical conditions.
Key Therapeutic Programs
- KB195 – Targets urea cycle disorder
- KB295 – Designed for ulcerative colitis
- KB174 – Addresses hepatic encephalopathy
- KB109 – Investigational treatment for COVID-19
Additional Research Focus Areas
The company is also advancing programs in:
- Multi-drug resistant infections
- Chronic kidney disease
- Atherosclerotic cardiovascular disease
- Cardio-metabolic syndrome
- Immuno-oncology
- Inflammatory bowel diseases
Strategic Collaborations
Kaleido Biosciences has established partnerships with leading institutions, including:
- Institute Gustave Roussy
- Washington University
- Janssen
Frequently Asked Questions
-
What is Kaleido Biosciences's (OTC-KLDO) current market cap?As of 08/02/2025, Kaleido Biosciences (including the parent company, if applicable) has an estimated market capitalization of $4,262 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Kaleido Biosciences (OTC-KLDO) rank globally by market cap?Kaleido Biosciences global market capitalization ranking is approximately 49729 as of 08/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.